Abstract:Key PointsSevere acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) are examples of emerging zoonotic coronavirus infections capable of person-to-person transmission that result in large-scale epidemics with substantial effects on patient health and socioeconomic factors. Unlike patients with mild illnesses that are caused by other human-pathogenic coronaviruses, patients with SARS or MERS coronavirus infections may develop severe acute respiratory disease with multi-organ failure. The case–fatality rates of SARS and MERS are approximately 10% and 35%, respectively.Both SARS and MERS pose major clinical management challenges because there is no specific antiviral treatment that has been proven to be effective in randomized clinical trials for either infection. Substantial efforts are underway to discover new therapeutic agents for coronavirus infections.Virus-based therapies include monoclonal antibodies and antiviral peptides that target the viral spike glycoprotein, viral enzyme inhibitors, viral nucleic acid synthesis inhibitors and inhibitors of other viral structural and accessory proteins.Host-based therapies include agents that potentiate the interferon response or affect either host signalling pathways involved in viral replication or host factors utilized by coronaviruses for viral replication.The major challenges in the clinical development of novel anti-coronavirus drugs include the limited number of suitable animal models for the evaluation of potential treatments for SARS and MERS, the current absence of new SARS cases, the limited number of MERS cases — which are also predominantly geographically confined to the Middle East — as well as the lack of industrial incentives to develop antivirals for mild infections caused by other, less pathogenic coronaviruses.The continuing threat of MERS-CoV to global health 3 years after its discovery presents a golden opportunity to tackle current obstacles in the development of new anti-coronavirus drugs. A well-organized, multidisciplinary, international collaborative network consisting of clinicians, virologists and drug developers, coupled to political commitment, should be formed to carry out clinical trials using anti-coronavirus drugs that have already been shown to be safe and effective in vitro and/or in animal models, particularly lopinavir–ritonavir, interferon beta-1b and monoclonal antibodies and antiviral peptides targeting the viral spike glycoprotein.

An overview of the novel coronavirus MERS-CoV

From SARS to MERS: Evidence and Speculation

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Middle East Respiratory Syndrome Coronavirus Could be a Priority Pathogen to Cause Public Health Emergency: Noticeable Features and Counteractive Measures

Middle East Respiratory Syndrome Coronavirus (Mers-Cov): Challenges in Identifying Its Source and Controlling Its Spread

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Epidemiology of Middle East respiratory syndrome and its prevention and control

Middle East respiratory syndrome coronavirus and development of vaccines and specific drugs for its control

A Novel Coronavirus 2019 Linked with Pneumonia in China: Current Status and Future Prospects

From SARS to MERS, Thrusting Coronaviruses into the Spotlight

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV

Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases

2019 Novel Coronavirus (2019-Ncov) and 2019-Ncov Pneumonia

A Review of Coronavirus Disease-2019 (COVID-19)

Current epidemiological and clinical features of COVID-19; a global perspective from China.

Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Coronaviruses — drug discovery and therapeutic options

Dysregulation of lung epithelial cell homeostasis and immunity contributes to Middle East Respiratory Syndrome coronavirus disease severity